Microbiotic Product (NBT-NM108) to Reduce Chemotherapy-Induced Diarrhea
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This phase II trial tests whether NBT-NM108 works in reducing chemotherapy-induced diarrhea
in patients with colon cancer that has spread to other places in the body (metastatic).
Irinotecan is one of the most used medicine for colon cancer, but it leads to diarrhea in
most patients receiving it and among some of them, severe diarrhea can occur. NBT-NM108 is a
high dietary fiber formula that is developed based on research findings that have shown that
high fiber diets can help maintain healthy bacteria in the gut and improve gut function.
Giving NBT-NM108 to patients with colon cancer receiving chemotherapy may help relieve or
lessen diarrhea symptoms and lead to improved tolerance of the chemotherapy drug, irinotecan.